The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...

Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy ...

The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and Enanta Pharmaceuticals that you may have missed. Recent biotech company acquisitions have put ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

U.S. main stock indexes inched up on Friday and small-cap stocks outperformed after a benign inflation report cleared the way ...